Pharmacogenetics of Pain Management in Zimbabwean Patients With Sickle Cell Disease
Pharmacogenomics · 2023
DOI: 10.2217/pgs-2023-0045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacogenomics, 2023. Verfasst von Nyasha Lorraine Mapira und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genomic Medicine, African Institute of Biomedical Science & Technology (AiBST), 911 Boronia Township, Beatrice, Zimbabwe. Hauptthemen laut MEDLINE: Pharmacogenetics, Anemia, Sickle Cell. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Bill and Melinda Gates Foundation, European & Developing Countries Clinical Trials Partnership.
Themen: Schmerzmanagement
Abstract (Originalsprache)
Background
Pain is a common cause of hospitalization in sickle cell disease (SCD) patients. Failure to effectively control pain remains a challenge in patient care. Materials & methods: The authors conducted a cross-sectional study to determine the effect of CYP2D6 and UGT2B7 polymorphisms on pain management in 106 Zimbabwean SCD patients. Participant information was collected on a questionnaire. Genotyping was conducted using the GenoPharm® pharmacogenomics open array panel containing CYP2D6 and UGT genetic variants implicated in opioid response.
Results
The reduced function alleles CYP2D6*17 and *29 had high frequencies of 15.9% and 12.9%, respectively. UGT2B7 rs73823859 showed a statistically significant correlation with pain levels (p = 0.0454).
Conclusion
This study demonstrated the role of UGT2B7 polymorphism in SCD patient pain management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Genomic Medicine, African Institute of Biomedical Science & Technology (AiBST), 911 Boronia Township, Beatrice, Zimbabwe.
- Department of Biotechnology, Chinhoyi University of Technology, Private Bag 7724, Chinhoyi, Zimbabwe.
- Child Adolescent Health Unit, Department of Primary Health Care, Faculty of Medicine & Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
- Sydney Brenner Institute for Molecular Bioscience (SBIMB), University of the Witwatersrand, Johannesburg, Gauteng, 2000, South Africa.
ORCID-Profile: Nyasha Lorraine Mapira, Roslyn Stella Thelingwani, Zedias Chikwambi, Patience Kuona, Collen Masimirembwa
Förderung
- NCI NIH HHS
- Bill and Melinda Gates Foundation
- European & Developing Countries Clinical Trials Partnership
- National Institutes of Health
Zitieren
APA
Mapira, N. L., Thelingwani, R. S., Chikwambi, Z., Kuona, P., & Masimirembwa, C. (2023). Pharmacogenetics of Pain Management in Zimbabwean Patients With Sickle Cell Disease. Pharmacogenomics. https://doi.org/10.2217/pgs-2023-0045
Vancouver
Mapira NL, Thelingwani RS, Chikwambi Z, Kuona P, Masimirembwa C. Pharmacogenetics of Pain Management in Zimbabwean Patients With Sickle Cell Disease. Pharmacogenomics. 2023. doi:10.2217/pgs-2023-0045
BibTeX
@article{Mapira2023,
author = {Mapira, Nyasha Lorraine and Thelingwani, Roslyn Stella and Chikwambi, Zedias and Kuona, Patience and Masimirembwa, Collen},
title = {Pharmacogenetics of Pain Management in Zimbabwean Patients With Sickle Cell Disease},
journal = {Pharmacogenomics},
year = {2023},
doi = {10.2217/pgs-2023-0045}
}
EUVIMED